Cactus Juice Marketers to Pay $3.5 Million in Refunds to Consumers for Deceptive Claims that Their Product Treats Diseases
Date
The settlement with TriVita, Inc. is part of the FTC’s ongoing efforts to stop over-hyped health claims.
Displaying 741 - 760 of 1566
L’Oréal Settles FTC Charges Alleging Deceptive Advertising for Anti-Aging Cosmetics
Date
Cosmetics company L’Oréal USA, Inc. has agreed to settle Federal Trade Commission charges of deceptive advertising about its Lancôme Génifique and L’Oréal Paris Youth Code skincare products. According...
Jun23
Conditional Pricing Practices: Economic Analysis and Legal Policy Implications
The Federal Trade Commission and the Antitrust Division of the Department of Justice held a one-day public workshop on June 23, 2014 to explore the economics and legal policy implications of certain...
Akorn and Hi-Tech Pharmacal, In the Matter of
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. agreed to sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to settle FTC charges that Akorn’s proposed $640 million acquisition of Hi-Tech would be anticompetitive and lead to higher prices for consumers. The proposed order requires the parties to sell either Akorn’s or Hi-Tech’s rights and assets to each of the five drug products to Watson, and requires Akorn to assign Watson its contract for making branded and generic EMLA cream within 10 days after the deal is consummated. In addition, the companies must maintain the drugs to be sold as viable, marketable, and competitive pending their divestiture, and must allow the FTC to appoint a monitor to ensure that the companies comply with the order’s requirements.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
131 0221
Docket Number
C-4452
FTC Testifies Before Senate Commerce Subcommittee on Agency Efforts to Combat Fraudulent and Deceptive Claims for Weight-Loss Products
Date
FTC’s most recent fraud study shows that more consumers were victims of fraudulent weight-loss claims than of any other specific fraud type covered by the survey.
Statement of Chairwoman Edith Ramirez and Commissioner Julie Brill In the Matter of i-Health, Inc. and Martek Biosciences Corporation
Date
By
Edith Ramirez, Former Chairwoman;
Julie Brill, Former Commissioner
Matter Number
122 3067
Supplement Marketers Settle FTC Charges that “BrainStrong Adult” Memory Improvement Claims Are Deceptive
Date
Supplement marketers i-Health, Inc. and Martek Biosciences Corporation have agreed to settle FTC charges of deceptive advertising for claiming that their BrainStrong Adult dietary supplement will...
Company Settles FTC Charges that Head Lice Prevention Claims Were Deceptive
Date
The Federal Trade Commission has charged personal care company Lornamead, Inc. with deceiving consumers with exaggerated claims that its “Lice Shield” shampoo, stick, and spray products will prevent...
FTC Charges Green Coffee Bean Sellers with Deceiving Consumers through Fake News Sites and Bogus Weight Loss Claims
Date
The Federal Trade Commission has sued a Florida-based operation that capitalized on the green coffee diet fad by using bogus weight loss claims and fake news websites to market the dietary supplement...
FTC Approves Final Consent Orders Settling Charges that Companies Deceptively Claimed Their Genetically Modified Nutritional Supplements Could Treat Diseases
Date
Following a public comment period, the Federal Trade Commission has approved final consent orders settling charges that two marketers of genetically customized nutritional supplements deceptively...
FTC Staff: Missouri Should Consider Changing Physician Supervision Requirements for Advanced Practice Registered Nurses
Date
Federal Trade Commission staff submitted written comments to Missouri State Representative Jeanne Kirkton in response to a request for comments on legislative proposals that would remove or change...
FTC Staff Comment Before the Missouri House of Representatives Regarding Missouri House Bills 1481 and 1491
Date
Matter Number
V140009
Staff submitted a comment, in response to a request by Representative Jeanne Kirkton of the Missouri House of Representatives, regarding Missouri House Bills 1481 and 1491. HB 1491 would allow APRNs...
File
Text of the Staff Comment
(61.89 KB)
FTC Announces Agenda, Panelists for Upcoming Seminar on Privacy Implications of Consumer Generated and Controlled Health Data
Date
The Federal Trade Commission announced the agenda and panelists for its upcoming seminar on the privacy ramifications of consumer generated and controlled health data, taking place on May 7 from 10 a...
Report
Banning Foreign Pharmacies from Sponsored Search: The Online Consumer Response
Date
Increased competition from the Internet has raised a concern of product quality for online prescription drugs. The Food and Drug Administration (FDA) prohibits the importation of unapproved drugs into...
FTC Approves Final Order Settling Charges That Community Health Systems, Inc.’s Acquisition of Health Management Associates Inc. was Anticompetitive in Two Local Markets
Date
Following a public comment period, the Federal Trade Commission has approved a final consent order settling charges that Community Health Systems, Inc.’s (CHS) $7.6 billion acquisition of rival health...
FTC Puts Conditions on Akorn Enterprises’ Proposed Purchase of Hi-Tech Pharmacal
Date
Akorn Enterprises, Inc. and Hi-Tech Pharmacal, Inc. will sell the rights and assets to three generic prescription eye medications and two generic topical anesthetics to Watson Laboratories, Inc., to...
Displaying 741 - 760 of 1566